Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

Abstract

Patients with progressive chronic kidney disease (CKD) commonly develop mineral and bone abnormalities and extraskeletal calcifications with following increased cardiovascular risk. A key pathophysiological role is played by hyperphosphatemia. Since diet and dialysis are often insufficient to control serum phosphorus levels, many patients require treatment with phosphate binders. Among them is lanthanum carbonate, an aluminum-free non-calcium-based compound. The present review summarizes the most recent literature data concerning the safety, efficacy and tolerability of lanthanum carbonate in patients with end-stage renal disease and hyperphosphatemia. The drug is taken orally as chewable tablets or powder with only minimal gastrointestinal absorption and resulting reduced risk of tissue deposition and systemic drug interactions. The dissociation of the drug in the acid environment of the upper gastrointestinal tract induces the release of lanthanum ions, which bind to dietary phosphate forming insoluble complexes then excreted in the feces. Even though there is no clear evidence that lowering serum phosphorus levels can improve patient-centered outcomes, a mortality benefit with all phosphate binders, especially non-calcium containing ones, is not excluded. Lanthanum carbonate has been suggested to decrease all-cause mortality but not cardiovascular event rate compared to other phosphate binders. It induces a lower suppression of bone turnover than calcium carbonate and calcium acetate and may improve systolic function and cardiac dimension compared to calcium carbonate. Moreover, the use of lanthanum carbonate has been associated with better nutritional status compared to other phosphate binders, lower risk for hypercalcemia than calcium-containing binders, and amelioration of mild metabolic acidosis contrary to sevelamer hydrochloride. Main adverse effects include nausea, alkaline gastric reflux, gastric deposition of lanthanum, gastrointestinal obstruction, subileus, ileus, perforation, fecal impaction, and reduction of gastrointestinal absorption of some drugs including statins, angiotensin-converting enzyme inhibitors and some antibiotics such as fluoroquinolones or tetracyclines.

Keywords:

• adverse effects
• chronic kidney disease-mineral bone disorder
• CKD-MBD
• hyperphosphatemia
• lanthanum carbonate
• phosphate binders

Introduction

Patients with progressive chronic kidney disease (CKD) commonly show typical alterations in calcium/phosphate, parathyroid hormone (PTH) and vitamin D metabolism with resulting abnormal bone turnover, morphology and strength, greater risk of bone fractures, development of calcifications at the vascular or other soft tissue level, and increased cardiovascular morbidity and mortality. The combination of these biochemical and clinical manifestations configures a syndrome defined as CKD-mineral bone disorder (CKD-MBD).¹

Several factors and processes contribute to CKD-MBD pathophysiology. The first step seems to be the gradual reduction in Klotho expression as kidney function declines.² Klotho is a fibroblast growth factor 23 (FGF23) tissue co-receptor and its decrease induces a progressive peripheral resistance to FGF23, whose serum levels consequently rise. FGF23 is secreted by osteoblasts and osteocytes and behaves as a phosphaturic hormone. In particular, it interacts with the FGF-receptor/α-Klotho co-receptor complex thus reducing phosphate reabsorption in the renal proximal tubule; it also induces down-regulation of 1α-hydroxylase and up-regulation of 24-hydroxylase with following reduction of 1.25-dihydroxyvitamin-D3 synthesis.³ FGF23 increase initially serves as a compensatory mechanism to counteract hyperphosphatemia. Nevertheless, it contributes to CKD-MBD pathogenesis over time due to its ability to decrease 1.25-dihydroxyvitamin-D3 production. This leads to secondary hyperparathyroidism and to abnormalities in calcium and phosphorus serum levels, with enhanced bone remodeling, extraskeletal calcifications, and further FGF23 release.⁴

As mentioned above, altered mineral metabolism plays a key role in cardiovascular risk in patients with end-stage renal disease (ESRD). Phosphorus, calcium, calcium-phosphorus product and PTH levels predict all-cause and cardiovascular mortality.⁵ Furthermore, FGF23 and Klotho dysregulation is associated with cardiac hypertrophy, arteriosclerosis and atherosclerosis.⁶

It follows that a proper clinical management of CKD-MBD and of its consequences is essential to preserve bone morphology and physiology, prevent adverse cardiovascular outcomes and reduce overall mortality.

In addition to recommending an appropriate dietary regimen aimed to limit food phosphate intake, the control of serum phosphorus and calcium levels and the prevention and treatment of secondary hyperparathyroidism frequently require a pharmacological approach⁷ that nowadays may take advantage of many classes of drugs acting through different mechanisms. They include: vitamin D sterols (cholecalciferol, calcitriol, ergocalciferol), active vitamin D analogs (alfacalcidol, paricalcitol, doxercalciferol), calcimimetics (cinacalcet, etelcalcetide, evocalcet) and phosphate binders, the latter being divided in calcium-containing (calcium acetate, calcium carbonate) and calcium-free agents (lanthanum carbonate, sevelamer carbonate, sevelamer hydrochloride, bixalomer, sucroferric oxyhydroxide).² In dialysis patients, the management of hyperphosphatemia also benefits from renal replacement therapy. An effective phosphate removal can be achieved by extending session duration, increasing dialysis frequency and switching to high-flux online hemodiafiltration, although the latter has not been confirmed in all clinical trials.⁸

The aim of the present narrative review is to summarize the most recent data about the safety, efficacy and tolerability of lanthanum carbonate in ESRD patients with hyperphosphatemia.

Pharmacokinetics and Mechanism of Action of Lanthanum Carbonate

Lanthanum carbonate [La₂(CO₃)₃] (Figure 1) is an aluminum-free non-calcium-based compound used for the treatment of hyperphosphatemia in patients with ESRD since 2004 in the USA and since 2006 in Europe.^9,10

Figure 1 Schematic representation of lanthanum carbonate structure [La₂(CO₃)₃].

After being taken as chewable tablets or oral powder, the drug is only minimally absorbed from the gastrointestinal tract^11,12 with a consequently low absolute bioavailability, which was equal to 0.00127 ± 0.0008% in a randomized Phase I study involving healthy individuals.¹³ The small amount reaching the circulation almost completely binds to plasma proteins. Then, free lanthanum concentrations are very low with resulting reduced risk of tissue deposition. The poor absorption by the gut also explains the scarce probability of systemic drug interactions.¹⁴ However, lanthanum carbonate can reduce gastrointestinal absorption of some drugs, among which fluoroquinolones, due to its ability to form chelates with these molecules.¹⁵ More than 99% of lanthanum carbonate is excreted in the feces.¹² The minimal renal excretion accounts for the low risk of systemic accumulation in ESRD patients, which show a lanthanum exposure profile similar to that of subjects with normal kidney function.¹⁴

The drug works by dissociating itself in the acid environment of the upper gastrointestinal tract with release of lanthanum ions (La⁺), which bind to dietary phosphate resulting in insoluble lanthanum-phosphate complexes and net decrease in serum phosphate levels.^9,16 The action of all phosphate binders depends on gastric pH that influences both salt dissolution rate and binding reaction between ion and phosphate.¹⁷ The gastric pH corresponding to an optimal phosphate binder activity for lanthanum carbonate is 3–5, but the drug maintains the ability to carry out its function at pH 1–7.^18,19

Comparative Studies on Efficacy of Lanthanum Carbonate in Patients with End-Stage Renal Disease

PubMed database was searched on April 2020 for randomized controlled trials published between 2015 and 2020 using the terms “lanthanum carbonate” and “ckd” or “lanthanum carbonate” and “dialysis” or “lanthanum carbonate” and “hemodialysis” (Figure 2). Articles published in languages other than English were excluded. The main characteristics of the included trials are summarized in Table 1. Meta-analyses, post-hoc analyses and observational studies of interest were also briefly described to provide more complete information.

Table 1 Main Characteristics of the Included Trials

Endpoint	Ref	Study Design	No. of Patients	Study Population	Control	Follow-up Duration	Main Results in the Lanthanum Carbonate Group
Bone metabolism	20	Multicenter RCT	46, of whom 25 completed the study	HD patients	Calcium carbonate	24 wks	- Reduction of FGF23 and hepcidin - No difference in intact PTH, ALP, vitamin D, fetuin-A, osteopontin
	21	Prospective, open-label, parallel-group, multicenter trial	68	HD patients	Sucroferric oxyhydroxide	24 wks	- Reduction of iFGF23 to a lower extent compared to sucroferric oxyhydroxide
	24	Parallel design RCT	120, of whom 107 completed the study	CKD patients (eGFR 15–59 mL/min/1.73 m^2) with abnormal phosphorus balance	1) Calcium acetate 2) Dietary restriction	1 yr	- Reduction of bALP similar in the three groups - Suppression of PTH higher in the calcium acetate group
CV disease	25	Open-label randomized study	108, of whom 91 completed the study	CKD patients during the early period after starting HD	Calcium carbonate	18 mo.	- Amelioration in systolic function and cardiac dimension - Delayed development of coronary artery calcification only in patients where it was at a moderate stage
	26	RCT	92	HD patients with DM and adynamic bone disease	Calcium carbonate	12 mo.	- Slowing down of coronary artery calcification progression - Improvement in bone transport and bone density
	27	RCT	54	Elderly HD patients with skin itching	Routine HD alone	3 mo.	- Reduction of serum iPTH and phosphorus - Itching relief - Attenuation of vascular calcification
	29	RCT	43, of whom 41 completed the study	HD patients with type 2 DM	Calcium carbonate	2 yrs	- Slowed progression of brachial-ankle PWV without reaching statistical significance - No difference in IMT, BMD or fracture - Greater increase in OC/bALP ratio
	30	Ongoing multicenter, double-blind, parallel-group RCT (IMPROVE-CKD study)	Aimed recruitment of 488 patients	Patients with stage 3b-4 CKD	Placebo	96 wks	- Primary end-point: change in PWV - Secondary end-points: change in aortic calcification, serum phosphate, PTH and FGF23
Nutritional status	34	Multicenter RCT	110	Hypoalbuminemic HD patients	Two groups: - patients receiving high-protein meals + lanthanum carbonate during HD - patients receiving low-protein meals during HD Prescribed non-lanthanum phosphorus binders continued in both groups	8 wks	- Better nutritional status - Minor increase in inflammatory markers

Abbreviations: ALP, alkaline phosphatase; bALP, bone-specific ALP; BMD, bone mineral density; CV, cardiovascular; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23; HD, hemodialysis; iFGF23, intact FGF23; IMT, intima-media thickness; mo, month; OC, osteocalcin; PTH, parathyroid hormone; PWV, pulse wave velocity; RCT, randomized controlled trial; wks, weeks; yr, year.

Table 2 Clinical Aspects of Treatment with Lanthanum Carbonate

Key Points and Main Findings from Literature on Lanthanum Carbonate
Class	Aluminum-free non calcium-based phosphate binder
Composition	La2(CO3)3
Mechanism of action	Dissociation in the upper gastrointestinal tract with following binding of released lanthanum ions to dietary phosphate to form insoluble complexes, then excreted in the feces^Citation9,Citation16
Pharmacological features	Formulations: chewable tablets, powder Route of administration: oral Gastrointestinal absorption: minimal^Citation12 Absolute bioavailability: low (about 0.00127 ± 0.0008%)^Citation13 Excretion: >99% in feces; <1% in the urine^Citation12
Hard endpoints	Scarce evidence that therapeutic approaches aiming to lower serum phosphate can improve patient-centered outcomes but a mortality benefit with all phosphate binders, in particular non-calcium containing compounds, is not excluded^Citation48,Citation49 Decrease in all-cause mortality but not in cardiovascular event rate compared to other phosphate binders, in particular, calcium-based compounds^Citation32,Citation33
Soft endpoints	Low suppression of bone turnover compared to calcium carbonate and calcium acetate^Citation22,Citation24,Citation26 Decrease in serum FGF23 levels and trend of decline in hepcidin levels^Citation20 Systolic function and cardiac dimension significantly improved compared to calcium carbonate^Citation25 Lesser progression of coronary artery calcification compared to calcium carbonate^Citation26 Better nutritional status compared to other phosphate binders^Citation33,Citation34 Lower risk for hypercalcemia than calcium-containing phosphate binders^Citation31 Potential contribution to the correction of mild metabolic acidosis by increasing serum bicarbonate concentrations as opposed to sevelamer hydrochloride^Citation35,Citation36
Adverse effects	Gastrointestinal tract: nausea, alkaline gastric reflux, gastric deposition of lanthanum, gastrointestinal obstruction, subileus, ileus, perforation, fecal impaction^Citation17,Citation31,Citation40^–^Citation43 Reduced gastrointestinal absorption and decreased bioavailability of simultaneously administered drugs (angiotensin-converting enzyme inhibitors, statins, antibiotics such as tetracyclines or fluoroquinolones)^Citation15,Citation43 Scarce probability of systemic drug interactions^Citation14 No significant data for liver damage^Citation12,Citation39
Possible contraindications	Gastrointestinal diseases (active peptic ulcer, ulcerative colitis, Crohn disease)^Citation43

Abbreviation: FGF23, fibroblast growth factor 23.

Figure 2 Flow chart of selection of randomized controlled trials.

Numerous studies have assessed the effects of lanthanum carbonate on different endpoints.

Compared to calcium carbonate, lanthanum carbonate has been demonstrated to significantly reduce serum FGF23 and determine a trend of decline in hepcidin values whereas no difference was found between the two groups as regards intact PTH, alkaline phosphatase, vitamin D, fetuin-A, and osteopontin levels in hemodialysis patients.²⁰ However, in another study, intact FGF23 levels were lowered by sucroferric oxyhydroxide to a greater extent than lanthanum carbonate despite serum phosphate was similarly reduced in the two groups.²¹

More specifically concerning bone metabolism and pathophysiology, a Japanese study involving incident dialysis patients showed that lanthanum carbonate may prevent low bone turnover compared to calcium carbonate. Indeed, at 18 months, serum osteocalcin concentrations were significantly higher in patients receiving lanthanum carbonate than in those treated with calcium carbonate, and the percentage of low bone turnover, according to a cut-off value of serum bone-specific alkaline phosphatase, was appreciably lesser in the lanthanum carbonate group compared to the calcium carbonate group.²² However, sevelamer hydrochloride was able to reduce phosphorus, intact PTH and total alkaline phosphatase serum levels to a greater extent than lanthanum carbonate in patients undergoing hemodialysis, with no significantly different calcium levels between the two groups.²³ A randomized trial on 120 non-dialysis CKD patients with abnormalities in phosphorus balance compared lanthanum carbonate, calcium acetate and dietary restriction for a period of 1 year. The three interventions similarly reduced bone-specific alkaline phosphatase levels, indicating an improvement in bone turnover, but they did not significantly influence other biochemical or vascular parameters.²⁴

Given the association of hyperphosphatemia with cardiovascular disease and all-cause mortality, phosphate-lowering drugs are expected to positively influence clinical outcomes and improve prognosis of patients with ESRD.

The impact on cardiovascular calcifications of phosphate binders in general and of lanthanum carbonate in particular is controversial. A randomized open-label study on CKD patients examined the effects of lanthanum carbonate on the progression of coronary artery calcifications and cardiovascular abnormalities compared to calcium carbonate during the early period after starting renal replacement therapy. The use of lanthanum carbonate was associated with amelioration in systolic function and cardiac dimension. Moreover, it delayed the development of coronary artery calcification but only in patients where it was at a moderate stage.²⁵ Lanthanum carbonate also slowed down coronary artery calcification progression in hemodialysis patients with diabetes and adynamic bone disease compared to calcium carbonate,²⁶ and reduced itching and abdominal aortic calcification in elderly dialysis patients.²⁷

Nevertheless, no difference was found on the progression of cardiac valvular calcification between lanthanum carbonate and calcium carbonate 18 months after hemodialysis initiation compared to baseline.²⁸

Wada et al reported a potentially reduced progression of brachial-ankle pulse wave velocity in diabetic hemodialysis patients treated with lanthanum carbonate for 2 years but the difference with the group receiving calcium carbonate was not statistically significant.²⁹

Interesting data concerning the effects of lanthanum carbonate on cardiovascular outcomes in patients with stage 3b-4 CKD could emerge from the IMpact of Phosphate Reduction On Vascular End-points (IMPROVE)-CKD study, a double-blind, randomized placebo-controlled parallel-group trial that will assess pulse wave velocity after 96 weeks of lanthanum carbonate therapy versus placebo.³⁰

A network meta-analysis including 77 randomized clinical trials (12,562 participants), mostly conducted in dialysis patients, evaluated the impact of phosphate binders containing sevelamer, colestilan, bixalomer, lanthanum, iron compounds, calcium, nicotinic acid and calcium plus magnesium on mortality and other outcomes. All drugs reduced serum phosphorus concentrations to a greater extent than placebo, with iron-based agents proving to be the most effective ones. Trials were generally of short duration and no class of binders demonstrated to decrease mortality or cardiovascular complications compared to placebo. Additionally, lanthanum and sevelamer were associated with a significantly lower risk for hypercalcemia than calcium-containing phosphate binders.³¹ More recently, a meta-analysis of nine randomized controlled trials overall involving 2813 patients on maintenance hemodialysis examined the effect of lanthanum carbonate on all-cause mortality compared to other phosphate binders (calcium acetate, calcium carbonate, and sevelamer). All-cause mortality was significantly lower in patients treated with lanthanum carbonate but the cardiovascular event rate and serum phosphorus levels did not differ between the two groups. Lanthanum carbonate also decreased the risk of hypercalcemia.³²

Some studies have focused on other peculiar aspects of CKD that may benefit from lanthanum carbonate therapy.

In a cohort study involving chronic hemodialysis patients treated with lanthanum carbonate and other phosphate binders, those receiving lanthanum showed a better nutritional status compared to controls even though serum phosphorus decrease was similar in the two groups. This suggests that the use of phosphate binders and, in particular, of lanthanum carbonate may reduce the need for dietary phosphate restriction with consequent increase in protein intake and improvement in nutritional status.³³ Similar results had been achieved in a previous randomized controlled trial that demonstrated a better nutritional status, expressed by a rise in serum albumin, as well as a minor increase in inflammatory markers while controlling phosphorus levels in patients receiving high-protein meals during dialysis associated with lanthanum carbonate compared to those receiving low-protein meals.³⁴

Interestingly, it has been observed that phosphate binders may influence acid–base balance due to the presence in their molecules of constituents having acidotic or alkalotic properties. Also hyperphosphataemia plays a role, contributing to the condition of metabolic acidosis that is typical of CKD patients. Aluminum-containing and calcium-based binders (calcium carbonate and calcium acetate) partly compensate metabolic acidosis through different mechanisms whereas sevelamer hydrochloride favors metabolic acidosis because it binds phosphate ions in exchange of chloride, which is then buffered by bicarbonate. Lanthanum carbonate contains an alkali and has been demonstrated to increase serum bicarbonate concentration so improving metabolic acidosis.^35,36

Comparative Studies on Safety and Tolerability of Lanthanum Carbonate in Patients with End-Stage Renal Disease

Different studies regarding the safety of lanthanum carbonate have been conducted over the years, analyzing and comparing it with similar drugs used in the treatment of hyperphosphatemia in patients with ESRD.^37–39 In all considered works, it is highlighted that this drug represents an excellent therapeutic choice for the lower number of side effects and the greater long-term tolerability. In particular, Hutchinson and colleagues in 2016 published an overview on the safety profile of lanthanum carbonate during a period of 10 years, showing that there is still no evidence of adverse safety outcomes in patients with ESRD.¹²

The purpose of many studies was to evaluate the safety of the drug with respect to the potential effects on the gastrointestinal tract, on bone and liver metabolism, and the possible interactions with other drugs commonly used in ESRD.

Among the possible contraindications to the use of lanthanum carbonate, there is the presence of gastrointestinal diseases such as active peptic ulcer, ulcerative colitis, or Crohn disease. Gastrointestinal involvement has been carefully evaluated in several studies. The already cited network meta-analysis of randomized trials by Palmer and colleagues³¹ showed that lanthanum carbonate is associated with an increased risk of nausea compared to iron-based and calcium-based binders, whereas constipation was more frequent with sevelamer compared to calcium, lanthanum and iron. The use of lanthanum carbonate also seems to induce more frequent and longer lasting periods of alkaline gastric reflux, probably due to more prolonged dissolution time and higher production of CO₂ compared to sevelamer hydrochloride and sevelamer carbonate.¹⁷ Furthermore, numerous cases of gastric deposition of lanthanum have been described in dialysis patients; it is defined as “gastric lanthanosis” and is characterized by endoscopic bright-white spots and histological eosinophilic histiocytes.^40,41 In this regard, Yamada and colleagues reported the case of a 70-year-old man with ESRD due to diabetic nephropathy on hemodialysis and treated with lanthanum carbonate 1500 mg/day and lansoprazole 30 mg/day. After finding alterations of the gastric mucosa by routine esophagogastroduodenoscopy, a biopsy was performed and the histological examination showed the presence of groups of cells containing amphophilic fine granular material, identified as histiocytes after positive staining for CD68. Since the patient had been receiving lanthanum carbonate therapy for about 5 years, a histiocyte-mediated phagocytosis of lanthanum was hypothesized; the detection of phosphorus and lanthanum in the interstitium and histiocyte cytoplasm confirmed the suspected diagnosis.⁴² Treatment with lanthanum carbonate has been also associated with severe gastrointestinal complications including obstruction, perforation, subileus, ileus, and fecal impaction. One of the instructions to reduce the risk of serious adverse gastrointestinal events is to completely chew the tablets before swallowing them.⁴³

The therapeutic action against hyperphosphatemia represents one of the principal characteristics of phosphate binders, especially for the prevention and treatment of CKD-MBD. The safety profile of lanthanum carbonate was therefore assessed to analyze its relationship with bone metabolism, with most adverse events mainly related to the use of different binders from lanthanum carbonate.^2,44 Goto and colleagues evaluated the effects of the drug on bone markers and bone mineral density in patients new to hemodialysis, showing that patients undergoing lanthanum carbonate therapy had a minor percentage of low bone turnover compared to the group treated with calcium carbonate.²² This had been also previously reported in 2008 by Malluche and colleagues through bone histological assessment.⁴⁵ The influence of phosphate binders on vitamin D metabolism also shows that lanthanum carbonate is not associated with changes regarding any of the metabolites, while other binders lead to reduced serum levels of 1.25-dihydroxyvitamin-D3 and 24.25-dihydroxyvitamin-D3, that are related to negative consequences in CKD.⁴⁶

The link of lanthanum carbonate with the liver is very important since the hepatobiliary system represents its way of excretion.¹² For this reason, it should be used with caution in patients presenting biliary obstruction or hepatic impairment, because its elimination may be reduced. However, as evidenced by several trials and works over the years, there are no significant negative correlations nor the onset of liver-adverse events associated with long-term therapy.^12,39

Finally, it has been shown that the simultaneous administration of lanthanum carbonate with other drugs usually prescribed to patients with CKD, such as angiotensin-converting enzyme inhibitors, statins or antibiotics (tetracyclines or fluoroquinolones), could decrease their bioavailability.^15,43 This is mainly related to its ability of binding to drugs with anionic groups. Nevertheless, none of the drug interaction studies were performed with the maximum recommended therapeutic dose of lanthanum carbonate.

Use of Lanthanum Carbonate: From Current Guidelines to Clinical Practice

Patients with CKD and reduced renal phosphate excretion may present hyperphosphatemia. Higher serum phosphorus levels, in the context of abnormalities in mineral homeostasis, bone turnover and mineralization and vascular calcifications, predict worsened cardiovascular and all-cause mortality outcomes, both in non-dialysis and in dialysis populations.⁴⁷ Then, it is needed to reduce serum phosphorus concentrations and this can be achieved by restricting intake and/or increasing extrarenal phosphate removal. However, there is still scarce evidence that lowering serum phosphate can improve patient-centered outcomes, as also highlighted by the Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Guidelines updated in 2017.⁴⁸ On the other hand, existing data do not exclude that treatment could be beneficial in terms of mortality reduction.⁴⁹

The updated KDIGO guidelines on CKD-MBD management⁴⁸ suggest starting phosphate binder therapy in patients with CKD G3a-G5D and progressively or persistently elevated serum phosphate concentrations (recommendation 4.1.5), although this is still based on weak clinical evidence. Many drugs are available to counteract mineral metabolism abnormalities in patients with ESRD. Lanthanum carbonate belongs to the class of calcium-free phosphate binders and its main clinical characteristics are summarized in Table 2. Data from literature show that this drug may provide a survival benefit compared to other phosphate binders, especially calcium-based ones.^32,33 Nonetheless, potential effects of phosphate-lowering therapies on hard endpoints have not been unequivocally proven. Probably this occurs because hyperphosphatemia appears late compared to the first abnormalities of CKD-MBD, but starting phosphate binders when phosphorus serum levels are still normal would expose patients to adverse effects from these drugs for many years. In particular, as described above, the use of lanthanum carbonate can be associated with a variety of gastrointestinal adverse effects and requires caution especially in patients with pre-existing diseases at this level. Even more noteworthy, despite the established association between high phosphate and mortality, binder therapy in patients with CKD stage G3b or G4 and normal phosphate levels did not lead to the expected results in a recent trial. Indeed, the treatment only minimally decreased serum phosphate, had no effect on FGF23 and increased coronary calcifications compared to placebo.⁵⁰ Moreover, there is no evidence that a reduction in dietary phosphorus intake is able to improve clinical outcomes in patients with CKD G3a to G4,⁴⁸ even though the gradual increase in the production of phosphaturic hormones (FGF23, PTH) precisely originates from the need to maintain serum phosphorus within the normal range.² This compensatory mechanism is so efficient that hyperphosphatemia appears only when glomerular filtration rate is severely impaired, but the progressive increase in FGF23 and PTH concentrations is associated with higher cardiovascular risk.^5,6 Notwithstanding these pathophysiological assumptions, the lack of strong evidence from clinical trials has induced to focus the treatment only on patients with overtly increased phosphate levels,⁴⁸ emphasizing the need for future studies to evaluate the real effectiveness of hyperphosphatemia prevention in patients with CKD stage G3a to G5D at high risk for CKD-MBD, for example, based on FGF23 concentrations.

Conclusions

Treatment of hyperphosphatemia due to CKD with lanthanum carbonate is effective and well tolerated. The drug may induce a decrease in all-cause mortality compared to calcium-based phosphate binders but further studies are required to strengthen the evidence of a real survival benefit from lanthanum carbonate and other binders, especially in patients at higher risk.

Disclosure

The authors report no conflicts of interest in this work.